+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
TCR Therapy- Pipeline Insight, 2025 - Product Thumbnail Image

TCR Therapy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2024 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2024

  • Clinical Trials
  • December 2024
  • 280 Pages
  • Global
From
Recurrent Or Metastatic Head And Neck Cancer Market - Product Thumbnail Image

Recurrent Or Metastatic Head And Neck Cancer Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Oncolytic Virus Cancer Therapy Market - Product Thumbnail Image

Oncolytic Virus Cancer Therapy Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IPSC Derived NK Cells- Pipeline Insight, 2025 - Product Thumbnail Image

IPSC Derived NK Cells- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Tie-2 Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Tie-2 Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Pheochromocytoma- Pipeline Insight, 2025 - Product Thumbnail Image

Pheochromocytoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Toll-Like Receptor 8 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Toll-Like Receptor 8 Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more